David R Darley1,2, Lilibeth Carlos3, Stefanie Hennig4, Zhixin Liu5, Richard Day6,7, Allan R Glanville8. 1. Lung Transplant Unit, St Vincent's Hospital Darlinghurst, Sydney, Australia. David.Darley@svha.org.au. 2. UNSW Medicine, St Vincent's Hospital Clinical School, Sydney, Australia. David.Darley@svha.org.au. 3. Department of Pharmacy, St Vincent's Hospital Darlinghurst, Sydney, Australia. 4. School of Pharmacy, University of Queensland, Brisbane, Australia. 5. Department of Statistics, University of New South Wales, Kensington, Australia. 6. UNSW Medicine, St Vincent's Hospital Clinical School, Sydney, Australia. 7. Department of Clinical Pharmacology, St Vincent's Hospital Darlinghurst, Sydney, Australia. 8. Lung Transplant Unit, St Vincent's Hospital Darlinghurst, Sydney, Australia.
Abstract
AIMS: To (i) describe tacrolimus (TAC) pre-dose concentrations (C0), (ii) calculate apparent oral TAC clearance (CL/FHCT) adjusted for measured haematocrit (HCTi) and standardised to a HCT of 45%, across three observation time points and (iii) explore if low TAC C0 or high mean CL/FHCT are associated with an increased risk of rejection episodes early after lung transplantation. METHODS: TAC whole blood concentration-time profiles and transbronchial biopsies were performed prospectively at weeks 3, 6 and 12 after lung transplantation. The TAC pre-dose concentration (C0) was measured, and CL/FHCT was determined using non-compartmental analysis. The associations between TAC C0 and CL/FHCT and rejection status were explored using repeated measures logistic regression. RESULTS: Eighteen patients provided 377 TAC whole blood concentrations. Considerable variability around the median (IQR) CL/FHCT 6.8 (4.2-15.9) L h-1, and the median C0 12.7 (9.9-16.6) μg L-1 was noted. Despite adjustment for haematocrit, a significant decrease was observed in CL/FHCT in all patients over time: CL/FHCT 14 (5.4-23) at week 3, CL/FHCT 7.7 (4.5-12) at week 6 and CL/FHCT 3.9 (2.4-11) L h-1 at week 12 (p < 0.01). Seven (38.9%) patients experienced a single grade 2 rejection, whilst 11 (61.1%) patients experienced no rejection. Higher TAC C0 were associated with a reduced risk of rejection OR 0.68 (95% CI 0.51-0.91, p = 0.02), and greater mean CL/FHCT was associated with an increased risk of rejection OR 1.34 (95% CI 1.01-1.81 p = 0.04). CONCLUSION: Monitoring TAC C0, HCT and CL/FHCT in patients after lung transplantation may assist clinicians in detecting patients at risk of acute rejection and may guide future research into TAC and HCT monitoring after lung transplantation.
AIMS: To (i) describe tacrolimus (TAC) pre-dose concentrations (C0), (ii) calculate apparent oral TAC clearance (CL/FHCT) adjusted for measured haematocrit (HCTi) and standardised to a HCT of 45%, across three observation time points and (iii) explore if low TAC C0 or high mean CL/FHCT are associated with an increased risk of rejection episodes early after lung transplantation. METHODS:TAC whole blood concentration-time profiles and transbronchial biopsies were performed prospectively at weeks 3, 6 and 12 after lung transplantation. The TAC pre-dose concentration (C0) was measured, and CL/FHCT was determined using non-compartmental analysis. The associations between TAC C0 and CL/FHCT and rejection status were explored using repeated measures logistic regression. RESULTS: Eighteen patients provided 377 TAC whole blood concentrations. Considerable variability around the median (IQR) CL/FHCT 6.8 (4.2-15.9) L h-1, and the median C0 12.7 (9.9-16.6) μg L-1 was noted. Despite adjustment for haematocrit, a significant decrease was observed in CL/FHCT in all patients over time: CL/FHCT 14 (5.4-23) at week 3, CL/FHCT 7.7 (4.5-12) at week 6 and CL/FHCT 3.9 (2.4-11) L h-1 at week 12 (p < 0.01). Seven (38.9%) patients experienced a single grade 2 rejection, whilst 11 (61.1%) patients experienced no rejection. Higher TAC C0 were associated with a reduced risk of rejection OR 0.68 (95% CI 0.51-0.91, p = 0.02), and greater mean CL/FHCT was associated with an increased risk of rejection OR 1.34 (95% CI 1.01-1.81 p = 0.04). CONCLUSION: Monitoring TAC C0, HCT and CL/FHCT in patients after lung transplantation may assist clinicians in detecting patients at risk of acute rejection and may guide future research into TAC and HCT monitoring after lung transplantation.
Authors: P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz Journal: Nat Genet Date: 2001-04 Impact factor: 38.330
Authors: N A Undre; J van Hooff; M Christiaans; Y Vanrenterghem; J Donck; U Heeman; M Kohnle; B Zanker; W Land; J M Morales; A Andrés; A Schäfer; P Stevenson Journal: Transplant Proc Date: 1999 Feb-Mar Impact factor: 1.066
Authors: Javier G Blanco; Mathew J Edick; Michael L Hancock; Naomi J Winick; Thierry Dervieux; Michael D Amylon; Robert O Bash; Frederick G Behm; Bruce M Camitta; Ching-Hon Pui; Susana C Raimondi; Mary V Relling Journal: Pharmacogenetics Date: 2002-11
Authors: H Treede; W Klepetko; H Reichenspurner; A Zuckermann; B Meiser; T Birsan; W Wisser; B Reichert Journal: J Heart Lung Transplant Date: 2001-05 Impact factor: 10.247
Authors: Su-Jun Lee; Khawja A Usmani; Brian Chanas; Burhan Ghanayem; Tina Xi; Ernest Hodgson; Harvey W Mohrenweiser; Joyce A Goldstein Journal: Pharmacogenetics Date: 2003-08
Authors: Andreas Zuckermann; Hermann Reichenspurner; Tudor Birsan; Henrick Treede; Elena Deviatko; Bruno Reichart; Walter Klepetko Journal: J Thorac Cardiovasc Surg Date: 2003-04 Impact factor: 5.209